119 related articles for article (PubMed ID: 3773639)
1. A new simple mouse model for the in vivo evaluation of cholecystokinin (CCK) antagonists: comparative potencies and durations of action of nonpeptide antagonists.
Lotti VJ; Cerino DJ; Kling PJ; Change RS
Life Sci; 1986 Nov; 39(18):1631-8. PubMed ID: 3773639
[TBL] [Abstract][Full Text] [Related]
2. In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist.
Lotti VJ; Pendleton RG; Gould RJ; Hanson HM; Chang RS; Clineschmidt BV
J Pharmacol Exp Ther; 1987 Apr; 241(1):103-9. PubMed ID: 2437282
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.
Ito H; Sogabe H; Nakarai T; Sato Y; Tomoi M; Kadowaki M; Matsuo M; Tokoro K; Yoshida K
J Pharmacol Exp Ther; 1994 Feb; 268(2):571-5. PubMed ID: 7509389
[TBL] [Abstract][Full Text] [Related]
4. [Effect of cholecystokinin and its antagonists lorglumide, devazepide, and L-365,260 on gastrointestinal motility in rats].
Wang SX
Zhongguo Yao Li Xue Bao; 1993 Sep; 14(5):443-6. PubMed ID: 8010038
[TBL] [Abstract][Full Text] [Related]
5. Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors.
Gully D; Fréhel D; Marcy C; Spinazzé A; Lespy L; Neliat G; Maffrand JP; Le Fur G
Eur J Pharmacol; 1993 Feb; 232(1):13-9. PubMed ID: 7681406
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological effects of oxytocin on gastric emptying and intestinal transit of a non-nutritive liquid meal in female rats.
Wu CL; Hung CR; Chang FY; Pau KY; Wang PS
Naunyn Schmiedebergs Arch Pharmacol; 2003 Apr; 367(4):406-13. PubMed ID: 12690433
[TBL] [Abstract][Full Text] [Related]
7. CCK antagonists interact with CCK-B receptors on human small cell lung cancer cells.
Staley J; Jensen RT; Moody TW
Peptides; 1990; 11(5):1033-6. PubMed ID: 2178246
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.
Chang RS; Lotti VJ
Proc Natl Acad Sci U S A; 1986 Jul; 83(13):4923-6. PubMed ID: 3014520
[TBL] [Abstract][Full Text] [Related]
9. Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze.
Vasar E; Lang A; Harro J; Bourin M; Bradwejn J
Neuropharmacology; 1994 Jun; 33(6):729-35. PubMed ID: 7936110
[TBL] [Abstract][Full Text] [Related]
10. Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260.
O'Neill MF; Dourish CT; Iversen SD
Eur J Pharmacol; 1991 Feb; 193(2):203-8. PubMed ID: 2050197
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of CCK receptor antagonists on rat pancreatic secretion in vivo.
Niederau M; Niederau C; Strohmeyer G; Grendell JH
Am J Physiol; 1989 Jan; 256(1 Pt 1):G150-7. PubMed ID: 2463767
[TBL] [Abstract][Full Text] [Related]
12. Combined dose-ratio analysis of cholecystokinin receptor antagonists, devazepide, lorglumide and loxiglumide in the guinea-pig gall bladder.
Bishop LA; Gerskowitch VP; Hull RA; Shankley NP; Black JW
Br J Pharmacol; 1992 May; 106(1):61-6. PubMed ID: 1504732
[TBL] [Abstract][Full Text] [Related]
13. Proglumide, a cholecystokinin antagonist, increases gastric emptying in rats.
Shillabeer G; Davison JS
Am J Physiol; 1987 Feb; 252(2 Pt 2):R353-60. PubMed ID: 3812772
[TBL] [Abstract][Full Text] [Related]
14. Effect of two new cholecystokinin antagonists on gallbladder emptying in opossums.
Hanyu N; Dodds WJ; Layman RD; Hogan WJ; Colton DG
Am J Physiol; 1991 Feb; 260(2 Pt 1):G258-64. PubMed ID: 1996645
[TBL] [Abstract][Full Text] [Related]
15. Asperlicin: a unique nonpeptide cholecystokinin antagonist.
Zucker KA; Adrian TE; Zdon MJ; Ballantyne GH; Modlin IM
Surgery; 1987 Aug; 102(2):163-70. PubMed ID: 2441481
[TBL] [Abstract][Full Text] [Related]
16. Peripheral factors in the mediation of cholecystokinin-induced satiety as assessed by comparative potencies of cholecystokinin antagonists.
Murphy RB; Smith GP; Schneider LH; Gibbs J
Peptides; 1992; 13(1):77-81. PubMed ID: 1620660
[TBL] [Abstract][Full Text] [Related]
17. Involvement of cholecystokinin receptor in the inhibition of gastrointestinal motility by oxytocin in ovariectomized rats.
Wu CL; Doong ML; Wang PS
Eur J Pharmacol; 2008 Feb; 580(3):407-15. PubMed ID: 18078924
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo.
Taniguchi H; Yazaki N; Yomota E; Shikano T; Endo T; Nagasaki M
Eur J Pharmacol; 1996 Sep; 312(2):227-33. PubMed ID: 8894600
[TBL] [Abstract][Full Text] [Related]
19. Effect of cholecystokinin on gastric motility in humans.
Beglinger C
Ann N Y Acad Sci; 1994 Mar; 713():219-25. PubMed ID: 8185162
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a new CCK antagonist, L364,718: in vitro and in vivo studies.
Louie DS; Liang JP; Owyang C
Am J Physiol; 1988 Sep; 255(3 Pt 1):G261-6. PubMed ID: 2458681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
